Study Title
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma. (NCT01393717)

Trial Description
This phase II trial studies how well brentuximab vedotin (also known as SGN-035) before autologous (taken from an individual’s own cells) stem cell transplant works in treating patients with Hodgkin lymphoma (HL).

Monoclonal antibody-drug conjugates or ADCs such as brentuximab vedotin can block cancer growth in different ways by targeting certain cells.

This trial is sponsored by City of Hope Medical Center. [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
    • Drugs used in this trial
  • Phase: II
  • Estimated Enrollment: 57
  • Start: October 2011
  • Estimated Completion: September 2016 (Final data collection date for primary outcome measure)
  • Last verified: June 2015

Study Schemata 

Screen Shot 2016-07-06 at 4.31.34 PM

Last Editorial review: July 7, 2016
Information based on (NIH/NCI) and other sources.